The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy
Journal of Radiation Research · 2023
DOI: 10.1093/jrr/rrad001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiation Research, 2023. Verfasst von Shin-Ichiro Masunaga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Boron Neutron Capture Therapy, Osaka Metropolitan University, Sakai, Osaka, 599-8531, Japan. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Boron Neutron Capture Therapy, Head and Neck Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Human head and neck squamous cell carcinoma cells transfected with mutant TP53 (SAS/mp53) or neo vector (SAS/neo) were inoculated subcutaneously into left hind legs of nude mice. After the subcutaneous administration of a 10B-carrier, boronophenylalanine-10B (BPA) or sodium mercaptododecaborate-10B (BSH), at two separate concentrations, the 10B concentrations in tumors were measured using γ-ray spectrometry. The tumor-bearing mice received 5-bromo-2’-deoxyuridine (BrdU) continuously to label all intratumor proliferating (P) tumor cells, then were administered with BPA or BSH. Subsequently, the tumors were irradiated with reactor neutron beams during the time of which 10B concentrations were kept at levels similar to each other. Following irradiation, cells from some tumors were isolated and incubated with a cytokinesis blocker. The responses of BrdU-unlabeled quiescent (Q) and total (= P + Q) tumor cells were assessed based on the frequencies of micronucleation using immunofluorescence staining for BrdU. In both SAS/neo and SAS/mp53 tumors, the compound biological effectiveness (CBE) values were higher in Q cells and in the use of BPA than total cells and BSH, respectively. The higher the administered concentrations were, the smaller the CBE values became, with a clearer tendency in SAS/neo tumors and the use of BPA than in SAS/mp53 tumors and BSH, respectively. The values for BPA that delivers into solid tumors more dependently on uptake capacity of tumor cells than BSH became more alterable. Tumor micro-environmental heterogeneity might partially influence on the CBE value. The CBE value can be regarded as one of the indices showing the level of intratumor heterogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Boron Neutron Capture Therapy, Osaka Metropolitan University, Sakai, Osaka, 599-8531, Japan.
- Hanwa Daini Senboku Hospital, Sakai, Osaka 599-8271, Japan.
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan.
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-0801, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Masunaga, S. I., Sanada, Y., Takata, T., Tanaka, H., Sakurai, Y., Suzuki, M., Kirihata, M., & Ono, K. (2023). The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrad001
Vancouver
Masunaga SI, Sanada Y, Takata T, Tanaka H, Sakurai Y, Suzuki M, et al. The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy. Journal of Radiation Research. 2023. doi:10.1093/jrr/rrad001
BibTeX
@article{Masunaga2023,
author = {Masunaga, Shin-Ichiro and Sanada, Yu and Takata, Takushi and Tanaka, Hiroki and Sakurai, Yoshinori and Suzuki, Minoru and Kirihata, Mitsunori and Ono, Koji},
title = {The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy},
journal = {Journal of Radiation Research},
year = {2023},
doi = {10.1093/jrr/rrad001}
}
EUVIMED